Intracoronary Tirofiban on No-Reflow Phenomena

Status Completed

Clinical Trial Summary

The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary intervention (PCI).

Clinical Trial Description

The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients with ST-elevated myocardial infarction (STEMI). Re-canalization of infarct related arterial (IRA) flow related to better ventricular performance and lower mortality rate in patients with STEMI. In addition, no-reflow phenomena may limit the benefits of re-canalization of the IRA.

In recent years, many mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI. Although current guidelines recommend that small molecule GPI should be administered as an upstream bolus followed by a continuous infusion in patients with STEMI, changes in clinical practice may obviate the need for GPI dosage or routes in current practice. Previous studies have shown that intravenous and intracoronary administration of GPI improve the prognosis and significantly reduce mortality in patients with STEMI. Recently, the Ongoing Tirofiban in Myocardial infarction Evaluation-2 (ON-TIME 2) trial found that the use of tirofiban started during the pre-hospital phase as upstream therapy for primary percutaneous coronary intervention (PCI) and continued for up to 18 hours infusion after the procedure showed an improvement in the markers of reperfusion. Additionally, a reduction was demonstrated in the death in recurrent myocardial infarction in urgent target vessel revascularization and thrombotic bailout. However, in the current literature there are insufficient data regarding the role of intracoronary administration of GPI inhibitors in patients with STEMI who developed the no-reflow phenomenon. The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary PCI. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

No-Reflow Phenomenon

Clinical Trial Details

NCT number	NCT02054000
Study type	Interventional
Source	TC Erciyes University
Contact
Status	Completed
Phase	Phase 4
Start date	January 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03264859` - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction	N/A
Not yet recruiting	`NCT06342141` - Empagliflozin for No-reflow Phenomenon in PCI for STEMI	Phase 2
Not yet recruiting	`NCT04835974` - the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)	N/A
Recruiting	`NCT04785209` - Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Not yet recruiting	`NCT05360602` - Alpha Lipoic Acid Effect on No-Reflow Phenomenon	N/A
Not yet recruiting	`NCT05393557` - Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction	N/A
Completed	`NCT04699110` - Adrenaline for the Treatment of No-Reflow in Normotensive Patients	Phase 4
Completed	`NCT04573751` - The EPIVER Randomized Controlled Trial	N/A
Not yet recruiting	`NCT02233790` - Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI	Phase 4
Recruiting	`NCT05427786` - A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease	Phase 4
Completed	`NCT05355532` - Genetic Determinants of the Coronary Microvascular Obstruction in PCI

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.